MPD: Phenotype measures mapped to MP:0021121, abnormal rhythmic behavior

Phenotype measures associated with ontology term
MP:0021121 'abnormal rhythmic behavior'

All measures in this list are mapped to the ontology descendants of MP:0021121. None are mapped to MP:0021121 directly.

MP:0011396 abnormal sleep behavior
MP:0020467 abnormal circadian behavior

This MP term has been mapped to these MPD phenotype measurements to help users find relevant data. It should be noted that MPD measurements typically have a mixture of high-end, low-end and "normal" readings.

Sort/ Pick	Data set	Procedure / Protocol	Treatment	Phenotype Measure / Variable (click to view)	Panel	No. of Strains	Sex	Age	Sample Size (Avg)	Year
Chesler2:55	Chesler2	monitoring system	(none)	percentage of time spent sleeping, baseline [%] pct_sleep_daily 43481	CC diallel w/par	57	both	7-15wks	N=3	2011

Chesler2:56	Chesler2	monitoring system	(none)	percentage of time spent sleeping during dark period, baseline [%] pct_sleep_dark 43482	CC diallel w/par	57	both	7-15wks	N=3	2011

Chesler2:57	Chesler2	monitoring system	(none)	percentage of time spent sleeping, following sleep deprivation [%] pct_daily_deprivation 43483	CC diallel w/par	57	both	7-15wks	N=2	2011

Chesler2:58	Chesler2	monitoring system	(none)	percentage of time spent sleeping during dark period, following sleep deprivation [%] pct_dark_deprivation 43484	CC diallel w/par	57	both	7-15wks	N=2	2011

Chesler2:59	Chesler2	monitoring system	(none)	peak activity time from dark onset, following sleep deprivation [h] act_dark_deprivation 43485	CC diallel w/par	57	both	7-15wks	N=2	2011

Chesler3:81	Chesler3	monitoring system	(none)	percentage of time sleeping, baseline [%] pct_sleep 43581 total dark period	CC pre w/par	301	both	7-15wks	N=2	2011

Chesler3:83	Chesler3	monitoring system	(none)	percentage of time sleeping, after sleep deprivation [%] deprivation 43583 total dark period peak activity	CC pre w/par	301	both	7-15wks	N=2	2011

CSNA03:685	CSNA03	in vitro assay	(none)	peak-to-peak interval, indicating amount of time it takes for one cycle of bioluminescence circadian rhythm, in fibroblast cultures, founders [h] period_in 112539	inbred w/CC8	8	both	8-12wks	N=9	2020

CSNA03:686	CSNA03	in vitro assay	(none)	peak-to-peak interval, indicating amount of time it takes for one cycle of bioluminescence circadian rhythm, in fibroblast cultures, CC [h] period_cc 112544	CC w/par	40	both	8-12wks	N=4	2020

CSNA03:687	CSNA03	in vitro assay	(none)	peak-to-peak interval, indicating amount of time it takes for one cycle of bioluminescence circadian rhythm, in fibroblast cultures, DO [h] period_do 112549	DO population w/par	9	both	8-12wks	N=26	2020

CSNA03:688	CSNA03	in vitro assay	(none)	specific time point when bioluminescence reaches highest circadian rhythm amplitude (cycle number), in fibroblast cultures, founders [n] phase_in 112540	inbred w/CC8	8	both	8-12wks	N=9	2020

CSNA03:689	CSNA03	in vitro assay	(none)	specific time point when bioluminescence reaches highest circadian rhythm amplitude (cycle number), in fibroblast cultures, CC [n] phase_cc 112545	CC w/par	40	both	8-12wks	N=4	2020

CSNA03:690	CSNA03	in vitro assay	(none)	specific time point when bioluminescence reaches highest circadian rhythm amplitude (cycle number), in fibroblast cultures, DO [n] phase_do 112550	DO population w/par	9	both	8-12wks	N=26	2020

CSNA03:691	CSNA03	in vitro assay	(none)	peak-to-trough, indicating level of synchronization in circadian rhythm (max counts/s), in fibroblast cultures, founders [n/s] amplitude_in 112541	inbred w/CC8	8	both	8-12wks	N=9	2020

CSNA03:692	CSNA03	in vitro assay	(none)	peak-to-trough, indicating level of synchronization in circadian rhythm (max counts/s), in fibroblast cultures, CC [n/s] amplitude_cc 112546	CC w/par	40	both	8-12wks	N=4	2020

CSNA03:693	CSNA03	in vitro assay	(none)	peak-to-trough, indicating level of synchronization in circadian rhythm (max counts/s), in fibroblast cultures, DO [n/s] amplitude_do 112551	DO population w/par	9	both	8-12wks	N=26	2020

CSNA03:694	CSNA03	in vitro assay	(none)	number of days required for circadian rhythm amplitude to decrease to 36% of initial value, in fibroblast cultures, founders [days] damping_in 112542	inbred w/CC8	8	both	8-12wks	N=9	2020

CSNA03:695	CSNA03	in vitro assay	(none)	number of days required for circadian rhythm amplitude to decrease to 36% of initial value, in fibroblast cultures, CC [days] damping_cc 112547	CC w/par	40	both	8-12wks	N=4	2020

CSNA03:696	CSNA03	in vitro assay	(none)	number of days required for circadian rhythm amplitude to decrease to 36% of initial value, in fibroblast cultures, DO [days] damping_do 112552	DO population w/par	9	both	8-12wks	N=26	2020

CSNA03:697	CSNA03	in vitro assay	(none)	percentage of observed rhythms that fit expected sine wave, indicating stability and robustness of circadian rhythm, in fibroblast cultures, founders [%] goodness_of_fit_in 112543	inbred w/CC8	8	both	8-12wks	N=9	2020

Filter Table Results